
Opinion|Videos|August 20, 2025
Adherence to Alopecia Areata Therapies
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how adherence to conventional therapies for alopecia areata (AA) can be challenging, with adverse effects often impacting patient compliance, and how the most common cause of nonadherence is the lack of visible improvement or perceived efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Mostaghimi: How would you rate the overall adherence to conventional therapies in patients being treated for AA?
- Do the adverse effects of a patient's treatment typically affect adherence?
- What is the most common cause for nonadherence in patients with AA?
Advertisement
Related to this article

A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.

Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.

Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.

Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
3
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5


